British Journal of Cancer最新文献

The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-19 DOI: 10.1038/s41416-024-02934-x

Liang Luo, Ruiyan Wang, Lu Bai, Jin Shang, Xinyi Wang, Ruxi Chang, Weixuan Dong, Yang Li, Yan Li, Hua Liang, Hongjun Xie, Xiaoyi Duan

{"title":"The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.","authors":"Liang Luo, Ruiyan Wang, Lu Bai, Jin Shang, Xinyi Wang, Ruxi Chang, Weixuan Dong, Yang Li, Yan Li, Hua Liang, Hongjun Xie, Xiaoyi Duan","doi":"10.1038/s41416-024-02934-x","DOIUrl":"https://doi.org/10.1038/s41416-024-02934-x","url":null,"abstract":"Background: The diagnostic utility of prostate biopsy is limited for prostate cancer (PCa) in the prostate-specific antigen (PSA) grey zone. This study aims to evaluate the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for PSA grey zone PCa and clinically significant PCa (csPCa).Methods: A total of 82 patients with PSA levels ranging from 4 to 10 ng/mL who underwent 18F-PSMA-1007 PET/CT, mpMRI, and prostate biopsy were prospectively enrolled. For 18F-PSMA-1007 PET/CT and mpMRI in detecting PCa and csPCa, sensitivity, specificity, and area under the curve (AUC) were assessed using biopsy histology as the standard.Results: 18F-PSMA-1007 PET/CT demonstrated better diagnostic performance for PCa than mpMRI (AUC 0.81 vs. 0.63, P = 0.02). 11.0% of patients with PI-RADS 3-5 had no PCa on biopsy, of whom 77.8% were correctly differentiated by 18F-PSMA-1007 PET/CT. Combined 18F-PSMA-1007 PET/CT + mpMRI improved sensitivity (92.5% vs. 73.6%) and negative predictive value (NPV, 78.9% vs. 53.3%) compared with mpMRI alone.Conclusions: 18F-PSMA-1007 PET/CT outperformed mpMRI for detecting PCa in the grey zone level of PSA. 18F-PSMA-1007 PET/CT in combination with mpMRI has additional improvement in sensitivity and NPV for csPCa detection.Clinical trial registration: NCT05958004, 2024-07.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Women's perspectives of molecular breast imaging: a qualitative study.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-18 DOI: 10.1038/s41416-024-02930-1

Helen Elliott, A Joy Allen, Nerys D Forester, Sara Graziadio, W S Jones, Beverley Clare Lendrem, Mark S Pearce, Timothy Powell, Jason Scott, Alison Bray

{"title":"Women's perspectives of molecular breast imaging: a qualitative study.","authors":"Helen Elliott, A Joy Allen, Nerys D Forester, Sara Graziadio, W S Jones, Beverley Clare Lendrem, Mark S Pearce, Timothy Powell, Jason Scott, Alison Bray","doi":"10.1038/s41416-024-02930-1","DOIUrl":"https://doi.org/10.1038/s41416-024-02930-1","url":null,"abstract":"Background: Mammography has poor sensitivity in dense breast tissue. Retrospective studies suggest that Molecular Breast Imaging (MBI), has superior diagnostic accuracy to mammography in women with very dense breast tissue. Women's perspectives of MBI are unknown, but are crucial to understanding the feasibility of, and routes to, adoption into practice.Method: Semi-structured interviews with screened and unscreened women explored acceptability of MBI. Data were analysed thematically.Results: Four themes were generated from nineteen interviews: (1) presumed negative aspects of MBI are acceptable (2) convenience of access, (3) comfort in familiarity and (4) need for shared decisions relating to risk. Presumed negative aspects of MBI, such as radiation dose and forty-minute scan time, were acceptable provided there are benefits. Some participants were concerned about equitable access, such as parking. Participants expressed comfort in existing and familiar screening processes. Participants acknowledged that informing women of their breast density may result in increased anxiety, but it was still felt to be important to ensure women are fully informed of the risks and harms of screening.Conclusions: Women consider MBI to be an acceptable breast imaging modality. High-quality information enabling informed decision-making is essential.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-16 DOI: 10.1038/s41416-024-02933-y

Alessandro Villa, Bryan J Schneider, Christina Lacchetti, Thomas K Oliver, Douglas E Peterson

引用次数: 0

Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-16 DOI: 10.1038/s41416-024-02929-8

Chunliang Liu, Michael Reger, Hao Fan, Jintao Wang, Jianjun Zhang

{"title":"Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.","authors":"Chunliang Liu, Michael Reger, Hao Fan, Jintao Wang, Jianjun Zhang","doi":"10.1038/s41416-024-02929-8","DOIUrl":"https://doi.org/10.1038/s41416-024-02929-8","url":null,"abstract":"Background: Although phytoestrogens modulated pancreatic tumour growth in experimental studies, it remains unclear whether phytoestrogen intake is associated with pancreatic cancer.Methods: Of 92,278 persons who completed the Diet History Questionnaire in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, 346 were diagnosed with pancreatic cancer within a median follow-up of 9.4 years. Cox proportional hazards regression was used to evaluate pancreatic cancer risk in relation to phytoestrogen intake.Results: After adjustment for confounders, intakes of glycitein and formononetin were associated with a reduced risk of pancreatic cancer [highest vs. lowest quartile, hazard ratio (HR) (95% confidence interval (CI)) for glycitein: 0.60 (0.39, 0.92); P for linear trend: 0.01; HR for formononetin: 0.51 (0.37, 0.70); P for linear trend: 0.005]. These associations were stronger and their linear trends across the quartiles of intakes were more statistically significant among ever smokers than never-smokers. A reduced risk was also observed for ever smokers in the highest quartile of total isoflavones or daidzein compared with those in the lowest quartile.Conclusions: Our study suggests that high intakes of total isoflavones and some individual isoflavones were inversely associated with pancreatic cancer risk, but this potential protective effect was confined to ever smokers.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation. 通过构建预测模型和实验验证，确定前列腺癌相关疲劳的诊断生物标志物。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-15 DOI: 10.1038/s41416-024-02922-1

Ming Chen, Siqi Zhou, Xiongwei He, Haiyan Wen

{"title":"Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.","authors":"Ming Chen, Siqi Zhou, Xiongwei He, Haiyan Wen","doi":"10.1038/s41416-024-02922-1","DOIUrl":"https://doi.org/10.1038/s41416-024-02922-1","url":null,"abstract":"Background: Cancer-related fatigue (CRF) is a prominent cancer-related complication occurring in Prostate cancer (PCa) patients, profoundly affecting prognosis. The lack of diagnostic criteria and biomarkers hampers the management of CRF.Methods: The CRF-related data and PCa single-cell data were retrieved from the GEO database and clinical data was downloaded from the TCGA database. The univariate logistic/Cox regression analysis were used to construct the prediction models. The predictive value of models was analyzed using the ROC curve and Kaplan-Meier survival. The hub genes were screened by an intersection analysis of DEGs. The mice model of PCa and PCa-related fatigue were established, and fatigue-like behaviors of mice were detected. The expression of selected hub genes was validated by RT-PCR and IHC analysis.Results: The diagnosis and risk models showed great predictive value both in the training and validation dataset. Five genes (Baiap2l2, Cacng4, Sytl2, Sec31b and Ms4a1) that enriched the CXCL signaling were identified as hub genes. Among all hub genes, the MS4A1 expression is the most significant in PCa-related fatigue mice.Conclusions: We identified MS4A1 as a promising biomarker for the diagnosis of PCa-related fatigue. Our findings would lay a foundation for revealing the pathogenesis and developing therapies for PCa-related fatigue.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The long-lasting impacts of the COVID-19 pandemic on population-based cancer survival: what are the implications for data analysis? COVID-19 大流行对人群癌症存活率的长期影响：对数据分析有何意义？

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-14 DOI: 10.1038/s41416-024-02931-0

Rachael Stannard, Paul C Lambert, Georgios Lyratzopoulos, Therese M-L Andersson, Sam Khan, Mark J Rutherford

{"title":"The long-lasting impacts of the COVID-19 pandemic on population-based cancer survival: what are the implications for data analysis?","authors":"Rachael Stannard, Paul C Lambert, Georgios Lyratzopoulos, Therese M-L Andersson, Sam Khan, Mark J Rutherford","doi":"10.1038/s41416-024-02931-0","DOIUrl":"https://doi.org/10.1038/s41416-024-02931-0","url":null,"abstract":"Monitoring trends of cancer incidence, mortality and survival is vital for the planning and delivery of health services, and the evaluation of diagnostics and treatment at the population level. Furthermore, comparisons are often made between population subgroups to explore inequalities in outcomes. During the COVID-19 pandemic routine delivery of health services were severely disrupted. Resources were redeployed to COVID-19 services and patient risk of COVID-19 infection required serious consideration. Cancer screening services were paused, the availability of healthcare providers was reduced and, in some cases, patients faced difficulty in accessing optimal treatment in a timely manner. Given these major disruptions, much care should be taken when interpreting changes in cancer survival estimates during this period. The impact on cancer incidence and mortality statistics that have already been reported in some jurisdictions should drive further thought on the corresponding impact on cancer survival, and whether any differences observed are real, artificial or a combination of the two. We discuss the likely impact on key cancer metrics, the likely implications for the analysis of cancer registration data impacted by the pandemic and the implications for comparative analyses between population groups and other risk factor groups when using data spanning the pandemic period.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing radiomics from contrast-enhanced mammography in breast cancer.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-12 DOI: 10.1038/s41416-024-02932-z

Xuewei Wu, Ye Ling, Shuixing Zhang, Bin Zhang

引用次数: 0

Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-10 DOI: 10.1038/s41416-024-02917-y

Qing Wang, Yushuai Yu, Chenxi Wang, Zirong Jiang, Jialu Li, Xiaofen Li, Xiewei Huang, Ying Song, Zhenhui Li, Shicong Tang, Chuangui Song

{"title":"Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer.","authors":"Qing Wang, Yushuai Yu, Chenxi Wang, Zirong Jiang, Jialu Li, Xiaofen Li, Xiewei Huang, Ying Song, Zhenhui Li, Shicong Tang, Chuangui Song","doi":"10.1038/s41416-024-02917-y","DOIUrl":"https://doi.org/10.1038/s41416-024-02917-y","url":null,"abstract":"Background: Tertiary lymphoid structures (TLSs) impact cancer outcomes, including in triple-negative breast cancer (TNBC), where their role in immune modulation during neoadjuvant therapy (NAT) is underexplored.Methods: This study employed single-cell RNA sequencing (scRNA-seq), multiplex immunofluorescence (mIF) staining, and radiomic techniques to evaluate TLSs and the tumour microenvironment (TME) in TNBC patient samples before and after NAT.Results: The presence of TLSs in TNBC was associated with B-cell maturation and T-cell activation. Compared with TLS-low TNBC, TLS-high TNBC showed significantly greater expression of immunoglobulin family genes (IGHM and IGHG1) in B cells and greater cytotoxicity of neoantigen-specific CD8 + T cells (neoTCR8). Additionally, mIF revealed notable differences between TLSs and the TME in TNBC. Although CD8 + T-cell levels do not predict the NAT response effectively, TLS maturity strongly correlated with better NAT outcomes and prognosis (P < 0.05). An imaging biomarker scoring system was also developed to predict TLS status and NAT efficacy.Conclusion: Our results demonstrated changes in TLSs and the TME in TNBC patients post-NAT. These findings confirm the predictive value of mature TLSs (mTLSs) and support the use of personalised immunotherapy based on post-NAT immune characteristics, thereby improving clinical outcomes.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-10 DOI: 10.1038/s41416-024-02920-3

Bishma Jayathilaka, Farah Mian, Fanny Franchini, George Au-Yeung, Maarten IJzerman

引用次数: 0

Post-diagnosis statin use and survival among head and neck cancer patients: a cohort study in a universal health care system.

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-12-07 DOI: 10.1038/s41416-024-02925-y

Jie Lin, Michael I Orestes, Craig D Shriver, Kangmin Zhu

{"title":"Post-diagnosis statin use and survival among head and neck cancer patients: a cohort study in a universal health care system.","authors":"Jie Lin, Michael I Orestes, Craig D Shriver, Kangmin Zhu","doi":"10.1038/s41416-024-02925-y","DOIUrl":"https://doi.org/10.1038/s41416-024-02925-y","url":null,"abstract":"Background: Little research has been conducted on the relationship between statin use and the survival of head and neck cancer patients. This study assessed whether statin use after head and neck cancer diagnosis is associated with overall survival among patients in the U.S. military health system (MHS) that provides universal health care to its beneficiaries.Methods: The study included 1842 patients with head and neck squamous cell carcinoma (HNSCC) from MHS. Statin use was extracted from the pharmacy database of the Military Health System Data Repository (MDR). Time-dependent multivariate Cox proportional hazards models were used to assess the relationship between post-diagnosis statin use and overall survival with the adjustment for potential confounders.Results: Compared to non-users, increased post-diagnosis cumulative use of statins (per one-year of use) conferred a significant improved survival with adjusted hazard ratio (HR) of 0.70 (95% Confidence Interval, CI = 0.55 to 0.90). When analysis was stratified by status of statin use prior to HNSCC diagnosis, the HRs were 0.31 (95% CI = 0.15-0.65) and 0.81 (95% CI = 0.59-1.11) for post-diagnosis users who also used it before HNSCC diagnosis and those who only used it after the diagnosis, respectively.Conclusion: Prolonged statin use was associated with improved survival among HNSCC patients in MHS.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0